Clinical Research Directory
Browse clinical research sites, groups, and studies.
Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on Tissue-resident Regulatory T Cells
Sponsor: Cambridge University Hospitals NHS Foundation Trust
Summary
The primary goals of this study are to compare the differences in tissue-resident Treg gene signature for activation, proliferation, and suppressive function using single-cell/-nucleus RNA sequencing in patients treated with ld-IL-2 compared to control grouped by individual tissue beds from in and around the heart. Additionally, tissue-resident Tregs will be compared to peripheral blood Tregs from the same patient to assess the differential effect of ld-IL-2 on the two compartments.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2026-03-31
Completion Date
2028-12-01
Last Updated
2026-05-28
Healthy Volunteers
No
Interventions
Interleukin-2 (Aldesleukin)
5 sequential days of treatment (1.5MIU/day subcutaneously) and, if needed, 1.5MIU/week doses until CABG surgery completed
Standard care
Standard care for patients with coronary artery disease undergoing CABG surgery
Interleukin-2 (Aldesleukin)
5 sequential days of treatment (2.0MIU/day subcutaneously) and, if needed, 2.0MIU/week doses until CABG surgery completed
Locations (2)
Royal Papworth Hospital NHS Foundation Trust
Cambridge, Cambridgeshire, United Kingdom
Addenbrooke's Hospital
Cambridge, Cambridgeshire, United Kingdom